HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.

Abstract
Several quinones have been found to be effective in the treatment of some forms of cancer; however, their cumulative heart toxicity limits their use. The cannabinoid quinone HU-331 [3S,4R-p-benzoquinone-3-hydroxy-2-p-mentha-(1,8)-dien-3-yl-5-pentyl] is highly effective against tumor xenografts in nude mice. We report now a comparison of the anticancer activity of HU-331 and its cardiotoxicity with those of doxorubicin in vivo. General toxicity was assayed in Sabra, nude and SCID-NOD mice. The anticancer activity in vivo was assessed by measurement of the tumors with an external caliper in HT-29 and Raji tumor-bearing mice and by weighing the excised tumors. Left ventricular function was evaluated with transthoracic echocardiography. Myelotoxicity was evaluated by blood cell count. Cardiac troponin T (cTnT) plasma levels were determined by immunoassay. HU-331 was found to be much less cardiotoxic than doxorubicin. The control and the HU-331-treated groups gained weight, whereas the doxorubicin-treated group lost weight during the study. In HT-29 colon carcinoma, the tumor weight in the HU-331-treated group was 54% smaller than in the control group and 30% smaller than in the doxorubicin-treated group. In Raji lymphoma, the tumor weight in the HU-331-treated group was 65% smaller than in the control group and 33% smaller than in the doxorubicin-treated group. In contrast to doxorubicin, HU-331 did not generate reactive oxygen species in mice hearts (measured by protein carbonylation levels and malondialdehyde levels). In vivo, HU-331 was more active and less toxic than doxorubicin and thus it has a high potential for development as a new anticancer drug.
AuthorsNatalya M Kogan, Michael Schlesinger, Maximilian Peters, Gergana Marincheva, Ronen Beeri, Raphael Mechoulam
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 322 Issue 2 Pg. 646-53 (Aug 2007) ISSN: 0022-3565 [Print] United States
PMID17478614 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Troponin T
  • cannabidiol hydroxyquinone
  • Cannabidiol
  • Malondialdehyde
  • Doxorubicin
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Blood Cell Count
  • Body Weight (drug effects)
  • Cannabidiol (analogs & derivatives, chemistry, pharmacology)
  • Cell Line, Tumor
  • Doxorubicin (chemistry, pharmacology)
  • Echocardiography
  • HT29 Cells
  • Heart (drug effects, physiopathology)
  • Humans
  • Lipid Peroxidation (drug effects)
  • Male
  • Malondialdehyde (metabolism)
  • Mice
  • Mice, Inbred NOD
  • Mice, Inbred Strains
  • Mice, Nude
  • Mice, SCID
  • Molecular Structure
  • Myocardium (metabolism, pathology)
  • Neoplasms (blood, drug therapy, pathology)
  • Protein Carbonylation (drug effects)
  • Troponin T (blood)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: